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Background. During the ﬁrst introduction of a group A meningococcal vaccine (PsA-TT) in 2010–2011 and its
rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have
been vaccinated.
Methods. The new vaccine effectiveness evaluation framework was established by the World Health Organiza-
tion and partners. Meningitis case-based surveillance was strengthened in PsA-TT ﬁrst-introducer countries, and
several evaluation studies were conducted to estimate the vaccination coverage and to measure the impact of vaccine
introduction on meningococcal carriage and disease incidence.
Results. PsA-TT implementation achieved high vaccination coverage, and results from studies conducted
showed signiﬁcant decrease of disease incidence as well as signiﬁcant reduction of oropharyngeal carriage of
group A meningococci in vaccinated and unvaccinated individuals, demonstrating the vaccine’s ability to generate
herd protection and prevent group A epidemics.
Conclusions. Lessons learned from this experience provide useful insights in how to guide and better prepare for
future new vaccine introductions in resource-limited settings.
Keywords. meningococcal group A; PsA-TT; vaccine evaluation framework; disease incidence; Africa
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To reduce the frequency of deadly outbreaks of menin-
gitis in Africa, the Meningitis Vaccine Project (MVP)
developed a novel group A meningococcal conjugate
vaccine (PsA-TT), manufactured by the Serum Institute
of India, Ltd. Licensed in India in 2009, PsA-TT was
prequaliﬁed by the World Health Organization (WHO)
in June 2010 and initially introduced in September
2010, when it was given to 1- to 29-year-olds who resided
in 3 highly endemic/epidemic countries in West Africa
(Burkina Faso, Mali, and Niger) with the support of the
Global Alliance for Vaccines and Immunization (Gavi).
Between 2011 and 2013, PsA-TT was introduced in a
phased approach to parts or all of 9 additional hyperen-
demiccountries (Chad,Cameroon,Nigeria,Benin,Ghana,
Senegal, Sudan, Gambia, and Ethiopia), representing a
target population of 150 million people vaccinated [1].
To coordinate the international effort to evaluate PsA-
TT effectiveness in Africa, the WHO Inter-country
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Support Team for West Africa (IST-WA) established a framework
to evaluate results. Several evaluation studies were planned in co-
ordination with international public health partners. This paper
describes the efforts to evaluate PsA-TT effectiveness, analyzes
the results of the evaluation studies obtained so far, discusses the
main constraints and challenges faced, and reviews lessons learned.
EVALUATION FRAMEWORK: GOALS,
OBJECTIVES, AND METHODS
The postlicensure PsA-TT evaluation studies, undertaken in
early-introducer countries (Burkina Faso, Mali, Niger, and
Chad), aimed to demonstrate the effectiveness and public health
impact of PsA-TT under ﬁeld conditions following its ﬁrst in-
troduction in Africa. Six objectives were identiﬁed:
1. Monitoring vaccination coverage following the mass vac-
cination campaigns. Vaccination coverage estimates, which may
be inﬂuenced by local implementation issues, are essential for
the interpretation of measurements of vaccine impact.
2. Estimating the reduction in disease burden (incidence and
prevalence) by analyzing national surveillance data collected be-
fore and after PsA-TT introduction.
3. Estimating vaccine effectiveness on carriage and herd pro-
tection through pre- and postvaccine studies.
4. Monitoring the immune response to the vaccine.
5. Undertaking cost and beneﬁt studies associated with
vaccination.
6. Evaluating the impact of the vaccine’s introduction on a
country’s national immunization program.
Not all countries, or regions within a country, had the capac-
ity to undertake vaccine evaluation studies.
Enhanced meningitis surveillance (EMS) was implemented in
meningitis belt countries several years before the introduction of
PsA-TT, using standardized operating procedures developed by
the WHO Regional Ofﬁce for Africa (AFRO) and WHO head-
quarters in Geneva [2]. Additional efforts to strengthen menin-
gitis case-based surveillance capacity prior to the introduction of
PsA-TT depended on speciﬁc evaluation needs and resources.
These resources included a health infrastructure able to detect
suspected meningitis cases and collect cerebrospinal ﬂuid
(CSF) samples; a well-functioning system for transporting speci-
mens to district, regional, and/or national laboratories; laboratory
capacity for Gram staining, rapid testing of CSF samples using
culture and a latex seroagglutination test; district capacity to ac-
curately monitor and evaluate the vaccination campaign; and an
ability to implement a system to detect, investigate, manage, and
document adverse events following immunization with PsA-TT.
In Burkina Faso, substantial efforts were made since 2009 to
move the existing EMS system toward a stronger, laboratory-
conﬁrmed case-based surveillance system with ﬁnancial and
technical support from the Centers for Disease Control and Pre-
vention (CDC) and WHO. The EMS collects demographic case
data and CSF results obtained from a proportion of patients, as
recommended by the WHO EMS standard operating procedures
[2]. Before the 2010 national PsA-TT mass campaign, revised
case-based surveillance standard operating procedures for epi-
demic-prone diseases were implemented nationwide, following
an initial pilot phase that concentrated on 10 districts. The
scale-up of meningitis case-based surveillance in Burkina Faso
was accompanied by signiﬁcant efforts to improve specimen col-
lection and transport to the national reference laboratory, patho-
gen conﬁrmation with real-time polymerase chain reaction
techniques, introduction of a unique identiﬁer number to link lab-
oratory results to patients’ information, and improvement of data
management and data quality (completeness and timely report-
ing) [3, 4]. Similar efforts were undertaken in 3 health regions in
Chad during March–June 2012, with support from the MenAfri-
Car consortium, where 1- to 29-year-olds had been vaccinated
with PsA-TT in December 2011, except for one district [5]. In ad-
dition to these efforts to strengthen a move toward strong, labora-
tory-conﬁrmed, case-based surveillance in a restricted number of
countries, WHO and its partners continued to support the existing
EMS throughout the meningitis belt through refresher training,
provision of laboratory supplies, and monitoring and supervision.
Special studies were undertaken in Burkina Faso, Niger, and
Chad to measure the impact of PsA-TT on disease incidence,
meningococcal carriage, and herd protection [4–8]. Routinely
collected meningitis surveillance data were analyzed in the 3
countries [4–6]. In Burkina Faso, cross-sectional meningococcal
carriage studies were undertaken in a representative sample of the
1- to 29-year-old population before and after PsA-TT campaigns
by the Ministry of Health with technical and ﬁnancial support
from public health international partners including the Norwe-
gian Institute of Public Health, the CDC in Atlanta, and the
WHO Inter-country Support Team for West Africa [7, 8]. A
total of 45 847 oropharyngeal samples were analyzed [7, 8]. Similar
cross-sectional surveys were conducted in an age-stratiﬁed sample
of population in a rural area in Chad before and after PsA-TT in-
troduction, where a total of 10 277 samples were analyzed [5].
Three methods were used to estimate PsA-TT vaccination
coverage:
1. Administrative coverage. The fraction of the district/
health catchment area population belonging to the target
1- to 29-year-old age group was calculated and adjusted for
population growth. Administrative coverage was calculated by
dividing the number of people vaccinated (numerator) by the
vaccination target (denominator).
2. Independent monitoring. The independent monitoring
approach aimed to detect nonvaccinated at-risk groups (speciﬁc
age groups or geographic areas) to create innovative ways of
reaching these populations. Independent monitoring was
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conducted during the campaign (in-process monitoring) and
during the ﬁrst week after the completion of the campaign
(end-process monitoring). Monitoring was performed by inde-
pendent monitors using standardized forms. Two settlements
in a catchment area were selected randomly by the monitor,
and 5 households were visited in each settlement. In each
household visited, information was collected systematically on
the following variables:
(a) Number of people physically seen in a household by age
group.
(b) Total number of people with a vaccination card.
(c) Total number of people not vaccinated.
(d) Reason for nonvaccination (absence from the area, active
decision not to be vaccinated, vaccination post too far away,
long waiting times, no vaccinator at the vaccination post, and/
or lack of information).
(e) Information sources about the vaccine.
(f ) Awareness of potential side effects from the vaccine.
In addition to the household visits, a group of twenty 1- to 29-
year-olds was selected randomly and asked similar information
about vaccination as listed above. Having a vaccination card
that indicated that PsA-TT had been given was considered as
proof of vaccination. Vaccination coverage was calculated by di-
viding the number of people with vaccination cards (numerator)
by the total number of people physically seen (denominator).
3. Random coverage survey. In addition to the aforementioned
approaches, random coverage surveys were conducted at least 1
month after the vaccination campaigns. Two methods were
used to conduct these surveys: the stratiﬁed-cluster survey
method, recommended by the WHO Expanded Programme on
Immunization (EPI) [9, 10]; and the Lot Quality Assurance Sam-
pling (LQAS) method [11, 12]. The former provides age-group-
speciﬁc, sex, and subnational vaccination coverage estimates.
Countries adapted this method to their speciﬁc context. The
LQAS method was used to assess if eligible population subgroups,
deﬁned as Lots (age groups, sex, districts, etc) had achieved min-
imum acceptable vaccination coverage of 70%. Sampling frames
were derived from a previous population census and sample
sizes of subjects were calculated and divided into clusters with
the desired precision of 5%, assuming a coverage of 85%, a 95%
conﬁdence interval, and a design effect of 2. Lower and upper
coverage thresholds were set and decision values were deﬁned
in accordance with LQAS methods. Probability proportionate to
population size was used to select clusters in each district, as
described in 2-stage cluster sampling methods [10].
VACCINE IMPACT ON EPIDEMIC MENINGITIS
It was anticipated that, as with other conjugate vaccines, PsA-
TT would have 2 direct effects: (1) protection against invasive
meningococcal disease and (2) reduction of nasopharyngeal
carriage of meningococci. In addition, by preventing carriage,
the vaccine should reduce transmission of the meningococcus,
providing indirect protection to nonvaccinated subjects (herd
protection) and halting or preventing an epidemic.
DISEASE BURDEN REDUCTION
Because PsA-TT was licensed only on safety and immunogenic-
ity data, as with some other conjugate vaccines, measurement of
its postmarketing effectiveness was considered a public health
priority. Review of meningitis weekly incidence data, obtained
from the WHO Meningitis Weekly Bulletin, shows a marked
decline in the overall incidence of meningitis and a reduction
in the size of outbreaks in the African meningitis belt since
the time of the ﬁrst introduction of PsA-TT (Figure 1). In Bur-
kina Faso, where PsA-TT was ﬁrst introduced in 2010 through a
countrywide, mass vaccination campaign that reached 11.4 mil-
lion people aged 1–29 years, national population-based surveil-
lance data were collected for 14 years (1997–2010) before and
for 1 year after PsA-TT introduction (2011) [4]. Population es-
timates from the Burkina Faso National Institute of Statistics
and Demography were used to calculate the following para-
meters during the ﬁrst year after PsA-TT introduction and to
compare epidemic and nonepidemic years before vaccine
implementation: incidence of suspected and probable cases
of meningococcal meningitis by age group, mortality rate,
group-speciﬁc meningococcal disease incidence rates, and risk
of death [4]. Statistically signiﬁcant decreases in all causes of
meningitis, meningitis epidemics, and group A meningococcal
disease were found [4]. Decreases in suspected and probable
meningitis cases during the ﬁrst year after PsA-TT introduction
were noted compared with incidence rates during the lowest ep-
idemic years before vaccine introduction [4]. In Niger, where
PsA-TT was introduced in 2 phases, the last quarters of 2010
and 2011, similar analysis of routinely collected meningitis sur-
veillance and laboratory data of the period 2008–2011 was con-
ducted and showed a decline of incidence of group A cases as
observed in Burkina Faso, despite the fact that only 11 of the 42
districts of the country had been vaccinated after the ﬁrst phase
of the PsA-TT campaign (around 50% of the target population
for vaccination) [6]. The observed disappearance of group A
cases from the whole of Niger is likely related to both a natural
dynamic of meningitis epidemics in the belt and massive vacci-
nation with polysaccharide A/C vaccines in previous years [6,
13]. In Burkina Faso, it was not possible to compare vaccinated
and unvaccinated areas, as the whole country was covered with-
in a short period of time, and “before and after” analyses of vac-
cine impact can be affected by the changes in disease incidence
over time that are independent of vaccine introduction [6, 13].
PsA-TTwas introduced in Chad in December 2011, but the initial
PsA-TT Impact on Epidemic Meningitis • CID 2015:61 (Suppl 5) • S469
mass vaccination campaign covered only 3 regions (N’Djamena,
Chari-Baguirma, and Mayo-Kebbi) [5]. Vaccination of the
rest of the country continued the following year. This phased in-
troduction provided an opportunity to measure disease incidence
in vaccinated and unvaccinated population at the same time [5].
Comparison of the incidence of meningitis in the 3 regions where
PsA-TT campaigns had taken place with the areas that had not
been vaccinated showed that the epidemic had been halted in
the vaccinated areas, as well as a statistically signiﬁcant difference
between areas in the incidence of all cases of meningitis of 94%
[5]. Analysis of routinely collected surveillance data in Burkina
Faso, Niger, and Chad show strong evidence for a high level of
short-term vaccine effectiveness [4–6].
IMPACT ON DISEASE TRANSMISSION AND
HERD PROTECTION
The ability of PsA-TT to reduce disease transmission and
to generate herd protection was assessed by carriage studies
conducted in Burkina Faso and Chad. The overall results are
summarized in Table 1.
In Burkina Faso, the prevalence of meningococcal carriage
was measured in 3 geographically distinct districts before the in-
troduction of PsA-TT [7]. The overall baseline prevalence of
meningococcal carriage was 3.98%, with the highest carriage
rates being found among 15- to 19-year-old males and 10- to
14-year-old females, in rural districts, and during the dry season
Figure 1. Incidence of meningitis in the African meningitis belt, 2009–2014. Source: www.meningvax.org.


















Burkina Faso 20 326 80 0.39 22 093 0 0 NA .003
Chad 998a 6 0.6 5001b 1 0.02 98 (0.019
[.002–.138])
4278c 32 0.7
Source: [5, 7, 8].
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; NA, not applicable.
a First survey conducted September–November 2010 (13–15 months before vaccination).
b Third survey, conducted April–June 2012 (4–6 months after vaccination).
c Second survey, conducted August–October 2011 (2–4 months before vaccination).
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[7].Group Y was dominant (2.28%), followed by group X (0.44%),
group A (0.39%), and group W 0.35% [7]. Patterns of carriage
varied between surveys, but no group A carrier was found after
PsA-TT introduction in Burkina Faso, even among those who
were not vaccinated because they were too young or old at the
time of vaccination or had otherwise missed the vaccination cam-
paign [8]. In Chad, cross-sectional meningococcal carriage surveys
were conducted in the area where the ﬁrst PsA-TT campaigns
took place before and after vaccine introduction [5]. The preva-
lence of group A carriage dropped from 0.75% to 0.02% after
PsA-TT introduction [5]. In Chad, carriage of group A menin-
gococci fell after PsA-TT introduction in both vaccinated
and unvaccinated subjects. This is consistent with the meningitis
herd protection observed in both Burkina Faso and Chad [4, 5].
CHALLENGES IN MEASURING PSA-TT
EFFECTIVENESS
Since the ﬁrst introductions in 2010, measurements of the effec-
tiveness of PsA-TT have been conducted through the analysis of
routinely collected surveillance data before and after vaccine
introduction and through implementation of cross-sectional me-
ningococcal carriage surveys. Extensive investments in surveil-
lance and laboratory capacities were needed in countries such
as Burkina Faso and Chad. The success of PsA-TT introduction,
combined with the efforts to strengthen meningitis surveillance
with strong laboratory conﬁrmation of cases, has revealed chang-
es in the epidemiologic pattern of meningococcal disease: cases of
group A are disappearing, and consequently there has been an
increase in the proportion of cases due to other groups and
other bacteria (group W meningococci and pneumococci, re-
spectively) [4–6, 14]. Therefore, the key new challenges in mea-
suring PsA-TT long-term effectiveness include the need to
maintain a sustainable laboratory-conﬁrmed meningitis surveil-
lance system to accurately detect cases to use as a platform for
vaccine evaluation (including special studies) and ﬁnding ways
to maintain high vaccination coverage, either through follow-
up campaigns or introduction of PsA-TT into the routine EPI.
Despite successful deployment of PsA-TT and its demonstrated
short-term impact on epidemic meningitis, questions remain
about its longer-term impact. These include the duration of pro-
tection; whether there will be an emergence or spread of other
groups, serotypes, or other pathogens; how to determine corre-
lates of protection and kinetics of vaccine-induced immunity;
and what the immune response is in vaccine failure. We also
need to better understand the mechanisms that underlie indirect
protection offered by PsA-TT as well as use modeling to inform
both short- and long-term vaccination strategies [15]. These
methodological and programmatic challenges must be overcome
to assess the long-term effectiveness of PsA-TT. This long-term
assessment will need to include the use of PsA-TT in infants as
part of EPI, following prequaliﬁcation of the PsA-TT pediatric
indication by WHO.
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